Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ZEVRA THERAPEUTICS, INC. Director's Dealing 2021

Dec 1, 2021

32811_dirs_2021-12-01_ec89cbee-4ae0-47cc-b27a-94e1c168c5bf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: KEMPHARM, INC (KMPH)
CIK: 0001434647
Period of Report: 2021-12-01

Reporting Person: Plooster Matthew R (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-01 Common Stock A 2500 $8.44 Acquired 2500 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 1532 Direct
Common Stock 69 Indirect

Footnotes

F1: Held jointly with spouse.